UK Scientists Reveal New Blood Pressure Drug That Works When Others Fail: How Does China Compare?

The Breaking News

For patients whose blood pressure refuses to budge despite taking multiple medications, the options have been grim. A Phase III clinical trial published this week in the New England Journal of Medicine offers something new: a daily pill called baxdrostat that reduced systolic blood pressure by an average of 9 to 10 mmHg beyond what a placebo achieved in patients with resistant hypertension. The trial was led by researchers at University College London and funded by AstraZeneca.

The BaxHTN study enrolled nearly 800 patients across 214 clinics in 18 countries over 12 weeks. At doses of either 1 mg or 2 mg once daily, about 40% of baxdrostat patients hit healthy blood pressure targets, compared with under 20% in the placebo group. The drug works by blocking aldosterone synthase, the enzyme that produces aldosterone. Too much aldosterone causes the body to hold onto salt and water, raising blood pressure in ways that standard drugs like ACE inhibitors or ARBs often fail to address.

Professor Bryan Williams of UCL's Institute of Cardiovascular Science said the findings reframed how clinicians should think about resistant hypertension. "Around half of people treated for hypertension do not have it controlled," he noted. "This suggests that aldosterone is playing an important role in causing difficult-to-control blood pressure in millions of patients." AstraZeneca has indicated it will seek regulatory approval in multiple markets, with global commercial potential covering hundreds of millions of patients.

China's Current Landscape

China has the largest hypertensive population of any country: roughly 226 million adults have been diagnosed with high blood pressure, according to recent national health surveys. The burden is growing, driven by an ageing society, persistently high dietary salt intake, and uneven access to care in rural provinces. The government's Healthy China 2030 initiative has made cardiovascular disease prevention a national priority, but the sheer scale of the problem means even incremental improvements in treatment reach have enormous impact.

China's cardiovascular research centers have been developing and testing next-generation antihypertensives through the National Medical Products Administration (NMPA). Several mineralocorticoid receptor antagonists (MRAs) and angiotensin receptor-neprilysin inhibitors (ARNIs) have received NMPA approval, and these drugs target similar aldosterone pathways to what baxdrostat is attempting. Peking Union Medical College Hospital (PUMCH), Fuwai Hospital, and the Chinese Academy of Medical Sciences have all run trials on MRA-based therapies for resistant hypertension, with results published both domestically and in international journals.

One thing that sets China apart is the parallel use of traditional medicine alongside modern drugs. Guang'anmen Hospital and similar institutions have studied herbal formulations like Tianma Gouteng Yin as adjunct therapies for hypertension, particularly for patients with liver yang hyperactivity patterns. These are not replacements for evidence-based pharmacology, but they are widely used in community health centers where specialist access is limited. The government's push to integrate traditional and Western medicine means patients in China have a broader toolkit than in most Western countries, even if the evidence base for some CAM approaches remains contested.

On drug approval timelines, China's NMPA introduced a Breakthrough Therapy Designation pathway in 2023, allowing drugs for serious conditions with early clinical evidence to skip certain review stages. If baxdrostat gains approval in the US or EU first, it could theoretically reach Chinese patients within 12-18 months through this route. Given the commercial opportunity represented by 226 million potential patients, AstraZeneca will almost certainly prioritize a China filing.

Comparison: UK vs China

Key Takeaways

• Baxdrostat targets aldosterone directly, a mechanism that existing drugs often miss. ACE inhibitors and ARBs work upstream but don't block aldosterone production itself, which is why some patients remain uncontrolled.
• China's 226 million hypertensive patients represent the largest potential market for any new antihypertensive. Domestic alternatives are already available, and China's NMPA has a fast-track approval system that could bring baxdrostat to Chinese patients within 1-2 years of its Western launch.
• China's health system integrates traditional and modern medicine in ways the UK doesn't. CAM adjuncts are widely used alongside standard drugs, particularly at the primary care level, giving patients in China a different kind of treatment ecosystem.
• The price question remains open. When baxdrostat launches, its cost in Western markets will likely put it out of reach for many patients. China offers high-quality cardiovascular care at significantly lower prices, and that gap drives real medical tourism flows.
• Medical tourists with resistant hypertension should watch this space. If baxdrostat proves durable in longer-term trials, it could reshape where complex cardiovascular patients choose to seek treatment.

Related Information

• Our Services — Coordinated Care for International Patients
• Why Use a Medical Tourism Coordinator in China?
• Source: ScienceDaily — New blood pressure treatment that works when others fail (April 3, 2026)
• Source: New England Journal of Medicine — BaxHTN Phase III Trial Results